Effectiveness and Safety of Acupuncture and Moxibustion for Primary Dysmenorrhea: An Overview of Systematic Reviews and Meta-Analyses

Table 4

Reporting quality of the included reviews assessed by PRISMA.

Item	Checklist item PRISMA	Y		PY		N
		n (%)	95% CI	n (%)	95% CI	n (%)	95% CI
Tiltle
	Title	27 (96.43)	[0.89, 1.03]	0		1 (3.57)	[−0.03, 0.10]
Abstract
	Objectives	28 (100)		0		0
	Eligibility criteria	28 (100)		0		0
	Information sources	27 (96.43)	[0.89, 1.03]	0		1 (3.57)	[−0.03, 0.10]
	Risk of bias	7 (25)	[0.09, 0.41]	0		21 (75)	[0.59, 0.91]
	Included studies	23 (82.14)	[0.68, 0.96]	0		5 (17.86)	[0.04, 0.32]
	Synthesis of results	2 (7.14)	[−0.02, 0.17]	18 (64.29)	[0.47, 0.82]	8 (28.57)	[0.12, 0.45]
	Description of the effect	19 (67.86)	[0.51, 0.85]	0		9 (32.14)	[0.15, 0.49]
	Strengths and limitations of evidence	22 (78.57)	[0.63, 0.94]	0		6 (21.43)	[0.06, 0.37]
	Interpretation	28 (100)		0		0
	Funding	0		0		28 (100)
	Registration	1 (3.57)	[−0.03, 0.10]	0		27 (96.43)	[0.89, 1.03]
Introduction
	Rationale	27 (96.43)	[0.89, 1.03]	0		1 (3.57)	[−0.03, 0.10]
	Objectives	28 (100)		0		0
Methods
	Protocol and registration	4 (14.29)	[0.01, 0.27]	0		24 (85.71)	[0.73, 0.99]
	Eligibility criteria	27 (96.43)	[0.89, 1.03]	1 (3.57)	[−0.03, 0.10]	0
	Information sources	28 (100)		0		0
	Search	7 (25)	[0.09, 0.41]	21 (75)	[0.59, 0.91]
	Study selection	24 (85.71)	[0.73, 0.99]	2 (7.14)	[−0.02, 0.17]	2 (7.14)	[−0.02, 0.17]
	Data collection process	25 (89.29)	[0.78, 1.01]	1 (3.57)	[−0.03, 0.10]	2 (7.14)	[−0.02, 0.17]
	Data items	19 (67.86)	[0.51, 0.85]	2 (7.14)	[−0.02, 0.17]	7 (25)	[0.09, 0.41]
	Risk of bias in individual studies	13 (46.43)	[0.28, 0.65]	15 (53.57)	[0.35, 0.72]	0
	Summary measures	28 (100)
	Synthesis of results	25 (89.29)	[0.78, 1.01]	0		3 (10.71)	[−0.01, 0.22]
	Risk of bias across studies	21 (75)	[0.59, 0.91]	4 (14.29)	[0.01, 0.27]	3 (10.71)	[−0.01, 0.22]
	Additional analyses	17 (60.71)	[0.43, 0.79]	0		11 (39.29)	[0.21, 0.57]
Results
	Study selection	27 (96.43)	[0.89, 1.03]	0		1 (3.57)	[−0.03, 0.10]
	Study characteristics	27 (96.43)	[0.89, 1.03]	1 (3.57)	[−0.03, 0.10]	0
	Risk of bias within studies	27 (96.43)	[0.89, 1.03]	0		1 (3.57)	[−0.03, 0.10]
	Results of individual studies	28 (100)		0		0
	Synthesis of results	26 (92.86)	[0.83, 1.02]	1 (3.57)	[−0.03, 0.10]	1 (3.57)	[−0.03, 0.10]
	Risk of bias across studies	27 (96.43)	[0.89, 1.03]	1 (3.57)	[−0.03, 0.10]	0
	Additional analysis	15 (53.57)	[0.35, 0.72]	0		13 (46.43)	[0.28, 0.65]
Discussion
	Summary of evidence	8 (28.57)	[0.12, 0.45]	20 (71.43)	[0.55, 0.88]	0
	Limitations	26 (92.86)	[0.83, 1.02]	0		2 (7.14)	[−0.02, 0.17]
	Conclusions	26 (92.86)	[0.83, 1.02]	1 (3.57)	[−0.03, 0.10]	1 (3.57)	[−0.03, 0.10]
Funding
	Funding	10 (35.71)	[0.18, 0.53]	6 (21.43)	[0.06, 0.37]	12 (42.86)	[0.25, 0.61]

Y: yes; N: no; P: partial satisfaction.